Skip to content
Open access

Transcriptomic analysis reveals and validates lipid raft–associated biomarkers and functional networks in Alzheimer’s disease

Aug 2026 · IBRO Neuroscience Reports · Vol 21, pp. 625 - 638 · 0 citations · 82 references
Medicine

TL;DR

The findings suggest that lipid raft dysregulation may act as a key link between immune activation, mitochondrial dysfunction, and synaptic impairment in AD.

Abstract

Alzheimer’s disease (AD) involves complex changes, including synaptic dysfunction, neuroinflammation, and metabolic impairment, yet the role of lipid raft–associated gene networks in these processes remains unclear. In this study, we performed an integrative transcriptomic analysis using the GSE5281 dataset and validated the findings in an independent cohort (GSE33000). By combining differential expression analysis with weighted gene co-expression network analysis, we identified 72 lipid raft–associated genes linked to mitochondrial, synaptic, and immune-related pathways. Using network analysis and machine learning approaches (LASSO and SHAP), we further identified eight key biomarkers (CBL, CD44, EZR, FAS, FYN, ITGB1, MAPK1, and TGFBR1) that showed strong diagnostic performance and consistent results across datasets. Functional analysis revealed increased inflammatory signaling, including pyroptosis and cytokine pathways, alongside reduced oxidative phosphorylation and synaptic activity. Interestingly, immune profiling showed only minor differences in immune cell infiltration, but clear activation of multiple immune pathways, such as Th2 and Treg signaling, CD8⁺ T-cell signatures, and IL-6/IL-10–mediated inflammation. These immune changes were strongly associated with lipid raft–related biomarkers. Overall, our findings suggest that lipid raft dysregulation may act as a key link between immune activation, mitochondrial dysfunction, and synaptic impairment in AD.

Read PDF

Similar papers

Open access Aug 2026

Astrocytic HSP90AA1 Upregulation and Altered Synaptic Signaling in Parkinson’s Disease: Transcriptomic Screening and In Vivo Validation

Astrocytic upregulation of HSP90AA1 is associated with altered synapse-related intercellular communication patterns in the PD substantia nigra, potentially involving a predicted TP53 associated regulatory component.

Yi-Yuan Xu, Yanfeng Shi, Yan Li et al. · 0 citations
Open access Aug 2026

Lipid metabolism dysregulation in Parkinson’s disease: A Mendelian randomization and transcriptomic analysis

An integrative analysis identified DGKD, LEP, and GGPS1 as lipid metabolism-associated molecular signatures of PD and highlights GGPS1-mediated prenylation pathways as a potential mechanistic axis linking metabolic dysregulation to neurodegeneration.

F. Çalıkuşu, Su-Xiang Chen, Tao Wang et al. · 0 citations
Open access Aug 2026

Transcriptomic Signatures of Microglial Phagocytosis Reveal Diagnostic Markers and Immune Landscape in Alzheimer's Disease

This study identified five core signature genes that form a highly accurate diagnostic model validated in independent cohorts and identified two molecular subtypes with distinct immune features, constructed regulatory networks, and predicted potential therapeutics including Tamibarotene.

Hui-Min Chang, Yun Liu, Xiao-Jun Yang et al. · 0 citations
Open access Aug 2026

Peripheral blood microarray-based transcriptomic and epigenetic analyses identify immune, inflammation, and metabolic dysregulation in Alzheimer’s disease

Leveraging multi-omics to better understand the molecular signatures and pathways underlying Alzheimer’s disease (AD) pathogenesis is critical for early diagnosis and disease modifying interventions. We performed peripheral blood transcriptome (N = 669) and epigenome microarray analyses (N = 553) on non-Hispanic white...

Brendan A. Mitchell, I. Hausle, Sarah Smith et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.